Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 310,225,000, representing a 13.4% increase from HKD 273,615,000 in the same period of 2024[6] - Gross profit for the same period was HKD 254,084,000, up 10.2% from HKD 230,588,000, with a gross margin of 81.9% compared to 84.3% in 2024[6] - The company achieved a pre-tax profit of HKD 78,649,000, a 10% increase from HKD 71,543,000 in the previous year[7] - The company’s net profit reached approximately HKD 76.0 million, reflecting a year-on-year growth of 12.7%[38] - The total revenue for the group reached approximately HKD 310.2 million, representing a year-on-year growth of 13.4%[46] - Operating profit increased to HKD 79,407,000, compared to HKD 71,808,000 in the previous year, reflecting a growth of 10.9%[80] Research and Development - R&D expenses decreased by 34.7% to HKD 13,634,000 from HKD 20,890,000, accounting for 4.4% of revenue, down from 8.5%[6] - The company is advancing its R&D strategy by focusing on synthetic biology to drive innovation in regenerative medicine, targeting key therapeutic areas such as bone and skin regeneration[17] - Research and development expenses for the six months ended June 30, 2025, amounted to HKD 13,634,000, compared to HKD 23,312,000 for the same period in 2024[97] Market and Product Development - The Chinese pharmaceutical market is projected to grow from RMB 1,551.2 billion in 2018 to RMB 1,733.9 billion in 2024, with an expected reach of RMB 3,318.5 billion by 2035[9] - In the first half of 2025, 43 innovative drugs were approved in China, a 59% increase year-on-year, nearly matching the total of 48 approvals in 2024[9] - The company has six products on the market, including JinYinPeptide® and JinYinShu®[11] - Bogutai® achieved a significant revenue growth of 248.9% year-on-year since its launch in March 2024, reflecting strong market acceptance and clinical application[13] - JinYinKang® received approval from the NMPA on May 21, 2025, marking a key milestone in expanding the company's ophthalmic product portfolio[14] - The launch of GeneQueens™ and JinYinFu® represents a strategic expansion into the medical aesthetics sector, focusing on skin repair and post-operative recovery solutions[15][16] Financial Stability and Liquidity - The cash ratio improved to 1.69 from 0.53, indicating better liquidity management[6] - The company’s debt-to-equity ratio decreased to 45.2% from 58.9%, reflecting improved financial stability[6] - The current ratio increased from 2.58x to 3.40x, reflecting enhanced financial stability[55] - The debt-to-asset ratio improved to 31.1% as of June 30, 2025, down from 37.1% at the end of 2024, indicating better financial stability[66] Strategic Partnerships and Collaborations - The company has established strategic partnerships with API suppliers to secure high-quality raw materials at costs below the industry average, enhancing competitive advantage[14] - The company is collaborating with Chongqing Minji Medical Devices Co., Ltd. to develop recombinant collagen dressings, which received Class II medical device approval in 2024[31] - A collaboration agreement has been signed to jointly develop innovative weight loss drugs, aiming to address multiple key issues related to obesity treatment[29] Product Performance and Sales - The flagship product, Jinyin Peptide®, generated revenue of approximately HKD 107.8 million, an increase of 18.1% year-on-year, attributed to breakthroughs in retail channels and e-commerce expansion[40] - The revenue from the product Boshutai (® Acarbose Tablets) increased significantly by 84.8% to approximately HKD 6.1 million from about HKD 3.3 million, following its inclusion in a centralized procurement program[43] - The revenue from the product Bogutai (® Teriparatide Injection) surged by 248.9% to approximately HKD 65.6 million from about HKD 18.8 million, reflecting strong market promotion efforts[44] Employee and Operational Metrics - Employee costs, including directors' remuneration, increased to HKD 77,665,000 for the six months ended June 30, 2025, from HKD 64,281,000 in the same period of 2024, representing a rise of about 20.9%[98] - The group employed 504 staff members as of June 30, 2025, with a competitive compensation policy to attract and retain top talent[70] Shareholder Information - The largest shareholder, Liang Guolong, holds 1,816,650,464 shares, representing 30.42% of the total issued ordinary shares[121] - Automatic Result Limited holds 1,650,971,464 shares, representing approximately 27.65% of the total shares outstanding[126] - The total number of issued shares as of June 30, 2025, is 5,971,228,147[126] Corporate Governance and Reporting - The company’s interim report, including the condensed consolidated financial statements, has been reviewed by the audit committee[131] - The interim report is published on the Hong Kong Stock Exchange website and the company's official website[132] - No additional interests or short positions were disclosed by directors or key executives as of June 30, 2025[128]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]

Group 1 - The core point of the news is that Link Health Biotechnology Group has signed a strategic cooperation agreement with Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1] - Bogu Tai is a new generation osteoporosis treatment drug that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The cooperation area has over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai to enter these unmet market needs [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2] - The competitive pricing strategy is expected to yield higher profit margins for Bogu Tai, with revenue realization anticipated by the end of 2026 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 布 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 科 興 製 藥（ 股 票 代 碼 ： 688136.SH ）是 一 家 領 先 的 創 新 型 跨 國 生 物 製 藥 企 業 ， 其 設 立 並 運 營 6 家 海 外 子 公 司和 辦 事 處 ， 已 通 過 歐盟 、 巴 西 、 菲 律 賓 、 印度 尼 西 亞 等 全球幾十個國家和地區的市場准入並實現銷售。 聯康生物科技集團通過戰略合作拓展博固泰®全球市場 香港，二零二五年九月十二日 — 聯康生物科技集團有限公司（「本公司」），連同其 附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，其全資子公司北京博康健基 因科技有限公司（「北京博康健」）與科興生 ...

Core Viewpoint - Haier Smart Home (00690.HK) announced a share buyback of 200,000 A-shares at a cost of 5.32 million yuan, with the repurchase price ranging from 26.58 to 26.64 yuan per share [1] Group 1 - The company spent 5.32 million yuan on the buyback [1] - A total of 200,000 A-shares were repurchased [1] - The price per share for the buyback was between 26.58 and 26.64 yuan [1]

致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000,000 HKD | | 0.01 | HKD | | 5,000,000,000 | 本月底法定/註冊股本總額： HKD 5,000,000,000 第 1 頁 共 11 頁 v 1. ...

Core Viewpoint - The company reported a 13.4% year-on-year increase in revenue, reaching approximately HKD 310 million for the period ending June 30, 2025, alongside a record half-year profit of about HKD 76 million, reflecting a 12.7% year-on-year growth [1] Financial Performance - Revenue increased by 13.4% year-on-year to approximately HKD 310 million [1] - Half-year profit reached approximately HKD 76 million, marking a 12.7% year-on-year growth [1] - Earnings per share rose to approximately HKD 0.0127, reflecting a year-on-year increase of 16.5% [1] Strategic Focus - The company is refocusing its R&D strategy on the field of regenerative medicine [1] - It is exploring partnerships with leading regenerative medicine research institutions in China to develop innovative therapies utilizing growth factors and regenerative medicine technologies [1] - The aim is to leverage complementary strengths to accelerate research progress and further solidify the company's leadership position in biopharmaceutical innovation [1]